Assembly Biosciences
Assembly Biosciences' revenue rose 153.5% to $72 million in fiscal 2025. Its operating margin was −16.8%, up from −159.3% a year earlier. Free cash flow was −$41 million. The diluted share count rose 86.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Assembly Biosciences does
Assembly Biosciences is a biotechnology company developing treatments for serious viral diseases. It has no approved products. Its pipeline includes two long-acting drugs for recurrent genital herpes, an oral drug for hepatitis delta virus (HDV), and a drug meant to disrupt the replication of hepatitis B virus (HBV). It also has an oral drug for herpesviruses that affect transplant patients, and other research programs against viral targets.
Its work is tied to a collaboration with Gilead Sciences. In December 2025, Gilead exercised its option to license Assembly's herpes program, including its candidates ABI-1179 and ABI-5366. Assembly is moving that program to Gilead and, once Gilead gives it a development plan and budget, will decide whether to opt in to a profit share.
For HDV, Assembly is preparing a Phase 2 study of ABI-6250 and expects to start it in the fourth quarter of 2026. The company is not profitable and says it will need additional financing to complete its development work.
Its biggest risks, as it describes them
- It has no approved products and depends on the future success of its drug candidates.
- It is not profitable and will need additional financing for its development work.
- Its collaboration with Gilead is expected to be critical, and partners could delay or undermine its drugs.
- It relies on outside research organizations and manufacturers because it lacks its own facilities.
Income statement
Assembly Biosciences lost money in fiscal 2025: a net loss of $6 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 147 | 92 | 130 | 112 | 248 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Quick ratio | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
Cash flow
Projections
Project Assembly Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Assembly Biosciences shares on the open market, and 2 insiders sold $14,687.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Jeanette M BjorkquistPFO and PAO | Sold | 29 | $23.25 | $674 | Form 4 |
| Mar 30, 2026 | Jeanette M BjorkquistPFO and PAO | Sold | 328 | $26.69 | $8,755 | Form 4 |
| Mar 30, 2026 | Nicole S WhiteChief Manufacturing Officer | Sold | 197 | $26.69 | $5,258 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | 118.8% | 96.6% |
| Altman Z'' | −16.91 | −21.02 | −1.34 |
| Accruals ratio | −70.4% | 8.6% | 18.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Assembly Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences | FY25 | 153.5% | −16.8% | −56.9% | — | — | — | |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Rockwell Medical | FY25 | −31.8% | −6.8% | −1.7% | −17.4% | — | 3 | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Spero Therapeutics | FY25 | 39.2% | 9.4% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 9 | 15 | 16 | 79 | 6 | 0 | 7 | 28 | 72 |
| Revenue growth | — | — | 64.1% | 7.8% | 395.6% | −92.1% | −100.0% | — | 298.2% | 153.5% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 33 | 44 | 73 | 86 | 107 | 68 | 70 | 49 | 56 | 65 |
| Operating income | −45 | −52 | −93 | −103 | −65 | −133 | −94 | −65 | −45 | −12 |
| Net income | −44 | −43 | −91 | −98 | −62 | −130 | −93 | −61 | −40 | −6 |
| Diluted EPS (US$) | −2.57 | −2.41 | −3.98 | −3.72 | −1.75 | −3.00 | −23.08 | −13.38 | −6.69 | −0.55 |
| Diluted shares (millions) | 17 | 18 | 23 | 26 | 35 | 43 | 4 | 5 | 6 | 11 |
| Cash flow | ||||||||||
| Cash from operations | −35 | 2 | −65 | −84 | −63 | −93 | −84 | 23 | −51 | −41 |
| Capital expenditure | 0 | 1 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 |
| Free cash flow | −35 | 1 | −65 | −86 | −63 | −96 | −85 | 22 | −51 | −41 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 9 | 28 | 21 | 22 | 5 | 7 | 5 | 3 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 53 | 120 | 218 | 274 | 216 | 147 | 92 | 130 | 112 | 248 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 98 | 169 | 268 | 340 | 283 | 191 | 102 | 137 | 119 | 258 |
| Total liabilities | 18 | 56 | 57 | 67 | 43 | 22 | 19 | 96 | 86 | 51 |
| Shareholders' equity | 80 | 113 | 211 | 273 | 241 | 169 | 83 | 41 | 33 | 207 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | −579.1% | −626.4% | −643.4% | −81.9% | −2,121.7% | — | −902.5% | −159.3% | −16.8% |
| Net margin | — | −474.6% | −613.0% | −611.6% | −78.6% | −2,076.3% | — | −854.8% | −140.9% | −8.5% |
| Free cash flow margin | — | 11.0% | −441.1% | −536.4% | −80.2% | −1,542.9% | — | 313.9% | −179.3% | −56.9% |
| Rule of 40 (growth + FCF margin) | — | — | −376.9% | −528.5% | 315.4% | −1,635.0% | — | — | 118.8% | 96.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −44.6% | −44.4% | −56.1% | −40.4% | −24.2% | −63.4% | −74.0% | −99.0% | −107.9% | −5.1% |
| Return on assets | −38.2% | −32.0% | −41.5% | −32.1% | −19.9% | −54.8% | −63.6% | −51.3% | −31.4% | −3.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |